10-K: Barinthus Bio to Merge with Clywedog, Shifts Focus to Autoimmune Diseases Amidst Rising Losses

Barinthus Biotherapeutics plc announced a definitive all-stock merger agreement with Clywedog Therapeutics, Inc., refocusing its pipeline on immunology and inflammation while reporting increased net losses and a Nasdaq listing deficiency.

Summary

• Barinthus Biotherapeutics plc (BRNS) entered into an all-stock merger agreement with Clywedog Therapeutics, Inc. on September 29, 2025, with the combined company to be renamed Clywedog Therapeutics Holdings, Inc. (CLYD) and expected to close in Q2 2026.
• Existing Barinthus shareholders are expected to own approximately 34% of the combined company, while former Clywedog stockholders are expected to own approximately 66%.
• The company announced a strategic business refocus and restructuring in January 2025, prioritizing immunology and inflammation (I&I) indications, specifically VTP-1000 for celiac disease.
• As part of the refocus, a workforce reduction of approximately 65% was implemented, and the U.K. site is expected to close, with future operations concentrating at the U.S. site in Germantown, Maryland.
• The strategic changes are expected to extend the company's cash runway into 2027.
• VTP-1000, an antigen-specific immune tolerance candidate for celiac disease, is currently in a Phase 1 AVALON clinical trial, with the single ascending dose (SAD) portion showing VTP-1000 was well tolerated with a dose-dependent effect.
• The multiple ascending dose (MAD) portion of the VTP-1000 trial, including a gluten challenge, is ongoing, with data expected in the second half of 2026.
• Legacy infectious disease and oncology assets, including VTP-300 for chronic hepatitis B (CHB), VTP-500 for MERS, and VTP-850 for prostate cancer, have been deprioritized and will only be advanced with a partner.
• Phase 2 clinical trial data for VTP-300 in CHB, presented in May 2025, showed meaningful and sustained reductions in hepatitis B surface antigen (HBsAg), with 22% of participants achieving HBsAg loss at any timepoint and two patients achieving functional cure in the HBV003 trial.
• In a combination trial (IM-PROVE II) with Arbutus Biopharma's imdusiran, 25% of participants with low baseline HBsAg levels achieved functional cure, and 3 of 13 participants (23%) had undetectable HBsAg levels at week 48, all of whom seroconverted.
• The company received a deficiency letter from Nasdaq on January 6, 2026, for its ADSs closing below the minimum $1.00 bid price requirement for 30 consecutive business days, with a compliance period until June 29, 2026.
• The OUI License Agreement, which generated $15.0 million in revenue in 2024 from Vaxzevria sales, was terminated in February 2026, and no further payments from Vaxzevria sales are expected.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period marked by increased losses, declining cash reserves, significant workforce reduction, and a Nasdaq compliance issue, partially offset by a strategic merger aimed at future growth and pipeline focus.

Positives

• VTP-1000 Phase 1 AVALON trial (SAD portion) demonstrated good tolerability at all dose levels with no treatment-related serious adverse events (SAEs) and showed a dose-dependent pharmacological effect.
• VTP-300 Phase 2 data showed meaningful and sustained reductions in hepatitis B surface antigen (HBsAg), with 22% of participants achieving HBsAg loss and two patients achieving functional cure in the HBV003 trial.
• In a combination trial, VTP-300 contributed to functional cure in 25% of participants with low baseline HBsAg levels, with 23% achieving undetectable HBsAg levels and seroconversion.
• The strategic refocus on immunology and inflammation (I&I) indications, particularly VTP-1000, aims to leverage the proprietary SNAP-TI platform for immune tolerance.
• The restructuring and workforce reduction are expected to extend the company's cash runway into 2027.
• The merger with Clywedog Therapeutics, Inc. is expected to create a combined company with a differentiated portfolio targeting metabolic and autoimmune diseases, with four clinical data milestones anticipated within 18 months post-closing.

Negatives

• Net loss increased to $66.5 million for the year ended December 31, 2025, from $61.2 million in 2024.
• Cash, cash equivalents, and restricted cash decreased significantly to $71.9 million as of December 31, 2025, from $112.4 million in 2024.
• License revenue from Vaxzevria sales dropped to $0 in 2025 from $15.0 million in 2024, with no further payments expected due to the termination of the OUI License Agreement.
• The company incurred a $4.7 million impairment charge for acquired development technology intangible assets in 2025.
• A goodwill impairment expense of $12.2 million was recorded in 2024.
• A 65% workforce reduction was implemented, and the U.K. site is expected to close, indicating significant operational downsizing.
• Received a Nasdaq deficiency letter on January 6, 2026, for failing to meet the minimum $1.00 bid price requirement, risking delisting.
• The merger with Clywedog will result in significant dilution for current Barinthus shareholders, who are expected to own only 34% of the combined company.

Risks

• Failure to complete the Contemplated Transactions (merger with Clywedog) would have a material adverse effect on business, results of operations, financial condition, and stock price.
• Failure to successfully integrate the business with Clywedog in the expected timeframe would adversely affect future business and financial performance.
• Shareholders and Clywedog stockholders may not realize a benefit from the Contemplated Transactions commensurate with the ownership dilution they will experience.
• Business is exposed to inherent risks during the period prior to the closing of the Contemplated Transactions due to the effect of the announcement or pendency on business relationships, financial condition, operating results, and business.
• Litigation may arise in connection with the Contemplated Transactions, which could be costly, prevent consummation, divert management's attention, and harm the business.
• The company is subject to restrictions on business activities under the Merger Agreement.
• Significant losses have been incurred since inception, and losses are expected for at least the next several years, with no guarantee of achieving or maintaining profitability.
• No material revenue has been generated from product candidates, and profitability depends on successful clinical development, marketing approval, and commercialization.
• Further acquisitions or strategic partnerships may increase capital requirements, dilute shareholders, incur debt, or assume contingent liabilities.
• Limited operating history makes it difficult to evaluate business success and future viability.
• Raising additional capital may cause dilution, restrict operations, or require relinquishing rights to technologies or product candidates.
• Substantial additional funding is required, and inability to raise capital would compel delays, reductions, or elimination of product development programs or commercialization efforts.
• Inability to advance product candidates through clinical trials, obtain marketing approval or reimbursement, or experiencing significant delays, would materially harm the business.
• Clinical development is lengthy, expensive, and uncertain, with earlier results not predictive of future outcomes, potentially leading to substantial delays or inability to complete trials.
• Interim, topline, and preliminary data from clinical trials may change as more participant data become available and are subject to audit and verification.
• Product candidates are based on novel approaches, making time and cost of development difficult to predict.
• Product candidates may cause serious adverse events or side effects, halting development, preventing marketing authorization, limiting commercial potential, or resulting in negative consequences.
• Market opportunities for certain oncology product candidates may be relatively small, and estimates of target patient populations may be inaccurate.
• Failure to realize benefits from future collaborations, alliances, or licensing arrangements.
• Marketing authorization processes are lengthy, time-consuming, and unpredictable, potentially leading to substantial harm if approvals are not obtained or are for narrower indications.
• Ongoing regulatory obligations and continued regulatory review post-approval may result in significant additional expenses and penalties for non-compliance.
• Inability to obtain and maintain patent protection, or insufficient scope of protection, could allow competitors to commercialize similar products.
• Rights to develop and commercialize technology and product candidates are subject to third-party licenses, and non-compliance could lead to loss of important license rights.
• The pipeline prioritization and restructuring may be unsuccessful, lead to additional costs, disrupt operations, create workforce problems, or increase litigation.
• High dependence on key personnel, and failure to attract and retain qualified personnel could hinder business strategy implementation.
• Difficulties in managing organizational growth.
• Classification as a passive foreign investment company (PFIC) could result in adverse U.S. federal income tax consequences to U.S. Holders.
• Failure to regain compliance with Nasdaq listing requirements could lead to delisting and negatively impact stock price and capital market access.
• Risks associated with international operations could materially adversely affect the business.
• Claims of U.S. civil liabilities may not be enforceable against the company due to its English incorporation.
• Fluctuations in exchange rates between the U.S. dollar and pound sterling may increase investment risk and affect financial results.
• The price of ADSs is volatile, and holders could lose all or part of their investment.
• Holders of ADSs are not treated as holders of ordinary shares and may have limited voting rights.
• Limitations on the transfer of ADSs and withdrawal of underlying ordinary shares.
• Waiver of jury trial with respect to claims arising under the deposit agreement could result in less favorable outcomes.
• If securities or industry analysts do not publish research or publish inaccurate/unfavorable research, stock price and trading volume could decline.
• Reduced reporting requirements as an emerging growth company and smaller reporting company may make ADSs less attractive to investors.
• Increased costs and time commitment due to operating as an English public company listed in the U.S.
• Operating results may fluctuate significantly, making future results difficult to predict.
• No intention to pay dividends on ADSs, limiting returns to share value appreciation.
• English law capital structure decisions require shareholder approval, limiting flexibility.
• Shareholder protections under the U.K. City Code on Takeovers and Mergers may not apply.
• Rights of shareholders may differ from those of a U.S. corporation.
• Exclusive forum provisions in Articles of Association may limit shareholder ability to bring claims.
• Changes in U.S. tax law could adversely affect financial condition and results of operations.
• Inability to use net operating loss and tax credit carryforwards or benefit from favorable U.K. tax legislation.
• Disclosure controls and procedures may not prevent or detect all errors or fraud.
• Potential for securities class action litigation.
• U.K.'s withdrawal from the European Union (Brexit) could increase regulatory burden.

Future Outlook

The company expects to close its all-stock merger with Clywedog Therapeutics, Inc. in the second quarter of 2026, forming a combined entity focused on metabolic and autoimmune diseases with four clinical data milestones anticipated within 18 months post-closing. The multiple ascending dose (MAD) portion of the VTP-1000 clinical trial is ongoing, with data expected in the second half of 2026. The strategic refocus and restructuring are projected to extend the company's cash runway into 2027. Legacy infectious disease and oncology assets will only be advanced with a partner.

Management Comments

• "Helping patients and their families is the guiding principle at the heart of Barinthus Bio. We aim to achieve this by developing truly transformational and highly disease-specific immunotherapies."

Industry Context

StockSavvy.ai notes the company's strategic shift to immunology and inflammation (I&I) aligns with a growing focus on targeted therapies for autoimmune diseases, moving away from broad immunosuppression. The merger with Clywedog, a diabetes-focused company, indicates a broader portfolio strategy in metabolic and autoimmune diseases, potentially leveraging complementary expertise and expanding market reach. The deprioritization of infectious disease and oncology assets reflects a common industry trend of pipeline rationalization to conserve capital and focus on core strengths, especially for clinical-stage biopharmaceutical companies. The Nasdaq delisting notice highlights the challenging capital market environment for smaller biopharmaceutical companies.

Comparison to Industry Standards

• The company's VTP-300 Phase 2 results for chronic hepatitis B, showing HBsAg reductions and functional cure in some patients, are notable in an area where less than 10% of patients achieve functional cure with existing therapies, suggesting a potentially differentiated treatment modality.
• The strategic decision to deprioritize infectious disease and oncology programs, while common for smaller biotechs to focus resources, contrasts with larger pharmaceutical companies that often maintain diverse pipelines across multiple therapeutic areas.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• License revenue of $15.0 million in 2024 (nil in 2025) from Oxford University Innovation (OUI), a wholly-owned subsidiary of the University of Oxford, related to Vaxzevria commercial sales. The OUI License Agreement was terminated in February 2026.
• Expenses of $0.4 million in 2025 ($0.8 million in 2024) to OUI, primarily for patent costs.

Stakeholder Impact

• **Shareholders:** Significant dilution expected from the merger with Clywedog (34% ownership post-merger). Nasdaq delisting risk could negatively impact share liquidity and value. Increased losses and cessation of Vaxzevria revenue may reduce investor confidence.
• **Employees:** A 65% workforce reduction and U.K. site closure indicate significant job losses and operational restructuring, potentially impacting morale and retention of remaining key personnel.
• **Customers/Patients:** Strategic refocus on I&I, particularly VTP-1000 for celiac disease, aims to bring new therapies to patients with autoimmune conditions. Deprioritization of infectious disease and oncology programs means future development for these indications depends on finding partners.
• **Creditors:** Increased net losses and declining cash reserves could raise concerns about financial stability, although the cash runway is projected into 2027 and the merger is expected to bring additional investments.
• **Suppliers/Partners:** Changes in manufacturing and R&D focus, including reliance on third-party manufacturers and seeking partners for legacy assets, will impact relationships and potential new collaborations.

Next Steps

• Complete the multiple ascending dose (MAD) portion of the Phase 1 AVALON clinical trial for VTP-1000, with data expected in the second half of 2026.
• Close the all-stock merger with Clywedog Therapeutics, Inc., expected in the second quarter of 2026.
• Seek partnership opportunities for deprioritized legacy infectious disease and oncology assets (VTP-300, VTP-500, VTP-850).
• Regain compliance with Nasdaq's minimum bid price rule by June 29, 2026, potentially considering a reverse stock split.
• Integrate business practices and operations with Clywedog post-merger.
• Advance the differentiated portfolio of clinical-stage candidates targeting metabolic and autoimmune diseases, aiming for four clinical data milestones within 18 months of the merger closing.

Key Dates

Recommendation

The company faces significant financial deterioration, evidenced by increasing net losses, a substantial decline in cash reserves, and the complete loss of license revenue from Vaxzevria. The Nasdaq delisting warning further exacerbates investment risk. While the merger with Clywedog and strategic refocus on I&I offer potential long-term benefits, the immediate financial and operational challenges, coupled with the significant dilution for existing shareholders in the merger, present substantial uncertainties and risks. A seasoned investor would likely view the current situation as highly speculative with considerable downside risk in the short to medium term.

Keywords

Biopharmaceutical, Immunotherapy, Autoimmune Diseases, Celiac Disease, VTP-1000, SNAP-TI platform, Merger, Clywedog Therapeutics, Clinical Trials, Phase 1, Phase 2, Hepatitis B, VTP-300, Drug Development, Biotech, SEC Filing, 10-K, Nasdaq, Delisting Risk, Workforce Reduction, Cash Runway, Intellectual Property